We initially explored the mechanisms contributing to osimertinib resistance and observed a substantial increase in PDK1 levels in patients with NSCLC who exhibited osimertinib resistance (Fig. 2a). The gene discussed is PDK1; the disease is non-small cell lung carcinoma.